{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T10:38:06Z","timestamp":1792579086174,"version":"4.5.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tetracyclines remain useful options for Gram-positive infections, particularly when prolonged oral therapy is required. Doxycycline is attractive because of its oral bioavailability and tolerability, but many susceptibility systems report tetracycline or minocycline rather than doxycycline, creating uncertainty about within-class extrapolation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To examine the microbiological, pharmacokinetic\/pharmacodynamic (PK\/PD), interpretive and clinical evidence supporting cross-susceptibility among tetracycline-class agents in clinically relevant Gram-positive organisms and to define when surrogate results may reasonably support doxycycline use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a narrative review of PubMed\/MEDLINE and ScienceDirect (1990\u20132025), supplemented by current European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Clinical and Laboratory Standards Institute (CLSI) documents. Predefined search concepts covered resistance mechanisms, cross-susceptibility, PK\/PD and clinical outcomes. Primary microbiological, surveillance, PK\/PD and clinical studies and systematic reviews\/meta-analyses were prioritized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Cross-susceptibility is not uniform across the tetracycline class. Efflux mechanisms such as tet(K) and tet(L) may permit retained doxycycline or minocycline activity, whereas ribosomal protection mechanisms such as tet(M) and tet(O) are associated with broader reduced susceptibility. Interpretation is organism-, phenotype-, method- and breakpoint-dependent. Free-drug Area Under the Concentration-Time Curve (AUC)\/Minimun Inhibitory Concentration (MIC) is the principal PK\/PD index, but exposure targets vary by agent, pathogen, model and endpoint. Direct clinical evidence is heterogeneous and is strongest for selected staphylococcal osteoarticular infections and suppressive therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Organism-specific EUCAST or CLSI surrogate rules may provide sufficient microbiological support for doxycycline use without routine agent-specific MIC confirmation when the clinical context is appropriate. Direct doxycycline testing is particularly valuable when surrogate interpretation is unsupported, results are resistant or discordant or uncertainty could materially affect management of severe or deep-seated infection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkag353","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T09:39:00Z","timestamp":1792575540000},"source":"Crossref","is-referenced-by-count":0,"title":["Cross-susceptibility among tetracyclines in Gram-positive infections: microbiological basis, EUCAST\/CLSI guidance and clinical implications for doxycycline use"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9840-6556","authenticated-orcid":false,"given":"Francisco Javier","family":"Candel","sequence":"first","affiliation":[{"name":"Clinical Microbiology and Infectious Diseases, IdISSC & IML Health Research Institutes, Hospital Cl\u00ednico Universitario San Carlos , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayra","family":"Matesanz","sequence":"additional","affiliation":[{"name":"Hospital at Home, Internal Medicine, IdISSC Health Research Institute, Hospital Cl\u00ednico Universitario San Carlos , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Mu\u00f1oz-G\u00f3mez","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Internal Medicine, IdISSC Health Research Institute, Hospital Cl\u00ednico Universitario San Carlos , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5402-3334","authenticated-orcid":false,"given":"Jose L","family":"Del Pozo","sequence":"additional","affiliation":[{"name":"Infectious Diseases Division, Microbiology Service, Cl\u00ednica Universidad de Navarra , Pamplona ,","place":["Spain"]},{"name":"IdiSNA, Navarra Institute for Health Research , Pamplona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"key":"2026102105385529000_dkag353-B1","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1056\/NEJMoa1710926","article-title":"Oral versus intravenous antibiotics for bone and joint infection","volume":"380","author":"Li","year":"2019","journal-title":"N Engl J Med"},{"key":"2026102105385529000_dkag353-B2","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1093\/jac\/dkl224","article-title":"Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines","volume":"58","author":"Agwuh","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"2026102105385529000_dkag353-B3","doi-asserted-by":"publisher","first-page":"553","DOI":"10.5194\/jbji-10-143-2025","article-title":"Doxycycline in the management of sexually transmitted infections.","volume":"73","author":"Peyriere","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2026102105385529000_dkag353-B4","doi-asserted-by":"publisher","first-page":"143","DOI":"10.5194\/jbji-10-143-2025","article-title":"Oral tetracyclines for bone and joint infections: what do we know?","volume":"10","author":"Cartau","year":"2025","journal-title":"J Bone Joint Infect"},{"key":"2026102105385529000_dkag353-B5","author":"EUCAST."},{"key":"2026102105385529000_dkag353-B6","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing. 34th ed. CLSI Supplement M100","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2024"},{"key":"2026102105385529000_dkag353-B7","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1086\/647952","article-title":"Antimicrobial susceptibility testing: a review of general principles and contemporary practices","volume":"49","author":"Jorgensen","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2026102105385529000_dkag353-B8","doi-asserted-by":"publisher","first-page":"3675","DOI":"10.1128\/AAC.47.12.3675-3681.2003","article-title":"Ribosomal protection proteins and their mechanism of tetracycline resistance","volume":"47","author":"Connell","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2026102105385529000_dkag353-B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1574-6976.1996.tb00251.x","article-title":"Tetracycline resistance determinants: mechanisms of action, regulation of expression, genetic mobility, and distribution","volume":"19","author":"Roberts","year":"1996","journal-title":"FEMS Microbiol Rev"},{"key":"2026102105385529000_dkag353-B10","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1038\/s41564-019-0445-2","article-title":"Emergence of plasmid-mediated high-level tigecycline resistance genes in animals and humans","volume":"4","author":"He","year":"2019","journal-title":"Nat Microbiol"},{"key":"2026102105385529000_dkag353-B11","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.ijantimicag.2017.04.019","article-title":"Suppressive antibiotic therapy with oral doxycycline for Staphylococcus aureus prosthetic joint infection: a retrospective study of 39 patients","volume":"50","author":"Pradier","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"2026102105385529000_dkag353-B12","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/cis803","article-title":"Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America","volume":"56","author":"Osmon","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2026102105385529000_dkag353-B13","volume-title":"Antimicrobial Resistance in the EU\/EEA (EARS-Net)\u2014Annual Epidemiological Report 2023","author":"European Centre for Disease Prevention and Control","year":"2024"},{"key":"2026102105385529000_dkag353-B14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s15010-017-1077-1","article-title":"Suppressive antibiotic therapy with oral tetracyclines for prosthetic joint infections: a retrospective study of 78 patients","volume":"46","author":"Pradier","year":"2018","journal-title":"Infection"},{"key":"2026102105385529000_dkag353-B15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA\u2014a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge","year":"2019","journal-title":"Res Integr Peer Rev"},{"key":"2026102105385529000_dkag353-B16","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1128\/AAC.49.4.1636-1638.2005","article-title":"Presence of tetracycline resistance determinants and susceptibility to tigecycline and minocycline","volume":"49","author":"Fluit","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2026102105385529000_dkag353-B17","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing. 36th ed. CLSI Supplement M100","author":"Clinical and Laboratory Standards Institute","year":"2026"},{"key":"2026102105385529000_dkag353-B18","author":"The European Committee on Antimicrobial Susceptibility Testing (EUCAST)"},{"key":"2026102105385529000_dkag353-B19","author":"The European Committee on Antimicrobial Susceptibility Testing (EUCAST)"},{"key":"2026102105385529000_dkag353-B20","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.cmi.2025.10.011","article-title":"Tetracycline hydrochloride susceptibility for prediction of antimicrobial susceptibility to doxycycline, minocycline, and tigecycline against gram-negative and gram-positive bacteria","volume":"32","author":"Sfeir","year":"2026","journal-title":"Clin Microbiol Infect"},{"key":"2026102105385529000_dkag353-B21","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1080\/07853890.2022.2085881","article-title":"Re-establishing the utility of tetracycline-class antibiotics for current challenges with antibiotic resistance","volume":"54","author":"LaPlante","year":"2022","journal-title":"Ann Med"},{"key":"2026102105385529000_dkag353-B22","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ijid.2019.02.005","article-title":"Antibiotic penetration into bone and joints: an updated review","volume":"81","author":"Thabit","year":"2019","journal-title":"Int J Infect Dis"},{"key":"2026102105385529000_dkag353-B23","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1093\/jac\/dkae315","article-title":"Clinically important interactions of macrolides and tetracyclines with dietary interventions\u2014a systematic review with meta-analyses","volume":"79","author":"Wiesner","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2026102105385529000_dkag353-B24","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1136\/ejhpharm-2020-002445","article-title":"Burden of enteral supplement interactions with common antimicrobial agents: a single-centre observational analysis","volume":"29","author":"Hughes","year":"2022","journal-title":"Eur J Hosp Pharm"},{"key":"2026102105385529000_dkag353-B25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.diagmicrobio.2013.01.023","article-title":"Contemporary tetracycline susceptibility testing: doxycycline MIC methods and interpretive criteria (CLSI and EUCAST) performance when testing gram-positive pathogens","volume":"76","author":"Jones","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2026102105385529000_dkag353-B26","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.diagmicrobio.2013.01.022","article-title":"Contemporary potencies of minocycline and tetracycline HCl tested against Gram-positive pathogens: SENTRY Program results using CLSI and EUCAST breakpoint criteria","volume":"75","author":"Jones","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2026102105385529000_dkag353-B27","doi-asserted-by":"publisher","first-page":"1565111","DOI":"10.3389\/fmicb.2025.1565111","article-title":"Antibiotic resistance rates in Cutibacterium acnes isolated from patients with acne vulgaris: a systematic review and meta-analysis","volume":"16","author":"Zhu","year":"2025","journal-title":"Front Microbiol"},{"key":"2026102105385529000_dkag353-B28","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3654","article-title":"Antibiotic susceptibility of Cutibacterium acnes strains isolated from Israeli acne patients","volume":"100","author":"Sheffer-Levi","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"2026102105385529000_dkag353-B29","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1128\/AAC.01129-07","article-title":"Activity of tigecycline against coryneform bacteria of clinical interest and Listeria monocytogenes","volume":"52","author":"Salas","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2026102105385529000_dkag353-B30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.5194\/jbji-11-21-2026","article-title":"Fluoroquinolones vs. tetracycline agents combined with rifampicin for periprosthetic joint infections: a comparative study","volume":"11","author":"Gachet","year":"2026","journal-title":"J Bone Joint Infect"},{"key":"2026102105385529000_dkag353-B31","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1093\/jac\/dkae347","article-title":"Systematic review on oral antibacterial relay therapy for acute staphylococcal prosthetic joint infections treated with debridement, antibiotics and implant retention (DAIR)","volume":"79","author":"Gachet","year":"2024","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/11\/dkag353\/72221930\/dkag353.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/11\/dkag353\/72221930\/dkag353.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T09:39:03Z","timestamp":1792575543000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag353\/8960344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,10,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag353","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,10,6]]},"article-number":"dkag353"}}